Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 31;13:840388. doi: 10.3389/fimmu.2022.840388

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Chang, Liang, Lu, Tseng, Tsai, Tang, Sugata, Chen, Chen, Wu, Lin, Khoo and Angata

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

GCNT1 and ST6GALNAC4 expression levels are associated with the prognosis of patients with chronic lymphocytic leukemia (CLL). Shown are the Kaplan–Meier survival plots with logrank test for two subgroups dichotomized with the expression levels of ST6GALNAC4 (A) and GCNT1 (B) as well as for four subgroups with the expression levels of both genes (C) using the optimal cutoff fitted in the Cox proportional hazards model. High expression of ST6GALNAC4 (A) and low expression of GCNT1 (B) were associated with poorer prognosis in CLL patients (P = 0.00259 and < 0.0001, respectively; likelihood ratio test). In panel (C), the survival curves of four subgroups are significantly different (P = 0.00015), and the prognosis of GCNT1 ^low ST6GALNAC4 ^high patients was significantly poorer as compared with that of GCNT1 ^high ST6GALNAC4 ^low patients (P < 0.001, likelihood ratio test; see also Table 1 ).